The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Pharma Co. Signs License Agreement With Boston Medical Center
Source: Edward White (12/24/2024)

60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note.

FDA Expedites Review of Gene Therapy Co.'s Drug
Source: Streetwise Reports (12/23/2024)

Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold.

Medical Equipment Co. Shows Strong Profit Margin
Source: Dr. Douglas Loe (12/20/2024)

Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report.

Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors.

Biopharma Using AI to Find Promising Cancer Drug Candidates
Source: Streetwise Reports (12/19/2024)

Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development.